ADMA Biologics (ADMA) Tops Q3 EPS by 2c

ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $62.13 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline